Cone dystrophy is a genetic eye condition that affects the cone cells in the retina. People with cone dystrophy often notice blurry or reduced central vision and trouble seeing colors, and bright light can feel uncomfortable. Signs usually begin in childhood or the teen years and tend to progress over time. Most people live a normal lifespan, but vision loss can impact school, work, and daily tasks. Treatment focuses on vision aids, tinted lenses, low-vision rehabilitation, and regular eye care, and genetic testing may help explain why the condition appears in multiple family members.
Overview
Cone dystrophySymptoms
Cone dystrophy causes progressive trouble with central vision, making reading or recognizing faces hard. People often notice light sensitivity, glare, and fading or distorted colors. Early symptoms of cone dystrophy may begin in childhood or early adulthood.
Outlook and prognosis
Most people with cone dystrophy notice gradual changes in central vision, color seeing, and light sensitivity, often beginning in childhood or early adulthood. Vision typically declines over years, then stabilizes. Low-vision tools, tinted lenses, and support services help maintain independence.
Causes and risk factors
Cone dystrophy is usually caused by genetic changes affecting cone cells, inherited in autosomal dominant, recessive, or X-linked patterns; some cases arise spontaneously. Main risk is a family history or known gene variant; environmental or lifestyle causes are not established.
Genetic influences
Genetics plays a major role in cone dystrophy; many cases are inherited, with autosomal dominant, autosomal recessive, or X-linked patterns. Specific gene variants can affect age of onset and severity. Genetic testing helps confirm diagnosis, guide counseling, and inform family risks.
Diagnosis
Doctors suspect cone dystrophy from clinical features and retinal imaging (OCT) findings. Electroretinography confirms cone dysfunction. Genetic testing often provides the genetic diagnosis of cone dystrophy and can clarify inheritance.
Treatment and drugs
Cone dystrophy care focuses on protecting vision, easing light sensitivity, and supporting daily tasks. Options may include tinted lenses, low-vision aids, orientation training, and treatment of complicating issues like macular edema. Regular eye exams and genetic counseling guide planning.
Symptoms
Bright daylight may feel harsh, small print gets harder to read, and colors can look faded or off. Early features of cone dystrophy can include problems with color vision, light sensitivity, and loss of sharp central vision. Features vary from person to person and can change over time. Some forms appear in childhood while others start later, but most people keep normal side vision and night vision.
Bright light or glare can make vision wash out and feel uncomfortable. In cone dystrophy, daylight can feel harsher than indoor light. People may squint, need sunglasses, or prefer dim rooms.
Reds, greens, or blues may look faded or harder to tell apart. Everyday tasks like matching clothes or reading colored lines on graphs can take more effort. Colors can shift over time.
Fine detail in the center of vision becomes less sharp, while side vision stays clearer. Faces, price tags, or road signs at a distance may look smudged. You might move reading materials farther away or zoom in more.
A small missing patch can appear in the center of sight. This can make it hard to see the middle of words or a person’s nose while the outline remains. Clinicians call this a central scotoma, which means a gap in the center of vision.
How people usually first notice Cone dystrophy?
Many people first notice cone dystrophy when bright light suddenly feels harsh and uncomfortable, and colors seem faded or “off,” especially reds and greens. Reading signs or recognizing faces at a distance can become harder, with central vision looking blurred or patchy while side (peripheral) vision stays clearer; some also see a shimmering or flickering in daylight. For children and teens, parents or teachers may spot early clues like trouble with color-based tasks, squinting in sunlight, or frequent moves to brighter or dimmer spots in class—common first signs of cone dystrophy.
Types of Cone dystrophy
Cone dystrophy has a few recognized clinical variants. These relate to which light-sensing cells are affected and how quickly vision changes, and some track with specific gene changes found on testing. People may notice different sets of symptoms depending on their situation. Here are the main types to know about:
Progressive cone dystrophy
Vision loss in bright light gradually worsens over years. Color vision fades and reading or recognizing faces in daylight becomes harder. Night vision often stays better for longer.
Stationary cone dysfunction
Symptoms start early and remain relatively stable over time. Bright light glare, reduced central clarity, and color vision problems are present but do not steadily worsen. This is often called achromatopsia when color vision is severely reduced from birth.
Cone–rod dystrophy
Cones are affected first, then rods become involved. People initially struggle with daylight and color, and later develop night blindness and side-vision loss. Doctors sometimes classify symptoms as central versus peripheral as the condition evolves.
Isolated cone dystrophy
Only cone cells are involved without rod changes on testing. Daytime vision, color discrimination, and fine detail are the main challenges, while night and side vision remain relatively preserved. Early symptoms of cone dystrophy here often include light sensitivity and washed-out colors.
Genetic subtypes
Variants of cone dystrophy can be linked to different genes such as CNGA3, CNGB3, GUCA1A, or GUCY2D. The specific gene can influence age of onset, severity, and whether the course is stationary or progressive. Not everyone will experience every type.
What genetics can tell you about symptoms
Some people with cone dystrophy linked to CNGA3 or CNGB3 variants notice early central vision blurring, poor color discrimination, and light sensitivity because faulty cone cell channels can’t properly respond to light. Others with GUCA1A or GUCY2D changes develop similar symptoms earlier, often progressing faster.
Causes and risk factors
Cone dystrophy is usually caused by changes in genes that affect the cone cells in the retina. It can run in families in different ways, and sometimes appears as a new gene change with no family history. Family history is the main risk, so risk factors for cone dystrophy are mostly genetic. Some risks are written in our DNA, passed down through families. There are no proven environmental or lifestyle causes, but steps like not smoking and using UV protection may support eye health over time.
Environmental and biological risk factors
Cone dystrophy affects the cone cells in the retina that support sharp, color vision, so understanding risks can help explain when problems might arise or be noticed. Some risks are carried inside the body, others come from the world around us. The points below focus on biological and environmental factors tied to cone cell damage or conditions that can look similar to cone dystrophy. This context can also guide when to seek care if early symptoms of cone dystrophy appear.
Some forms of cone dystrophy are seen more often in males. Females can be affected, though usually less frequently. This pattern may guide testing when central vision or color changes appear.
Rare immune reactions can target the retina’s light-sensing cells and harm cones. This can cause vision problems that resemble cone dystrophy on testing. These reactions can occur with certain immune conditions or cancers.
Some medicines, including certain antimalarials and older antipsychotics, can injure the macula and cone cells. Damage can build slowly and may look like cone dystrophy during an eye exam. Regular eye monitoring is often recommended when these medicines are needed long term.
Direct viewing of the sun, welding arcs, or powerful lasers without protection can burn the central retina. The fovea’s cone cells are especially vulnerable to this kind of light injury. Even brief exposure can leave lasting central blur or color distortion.
Genetic risk factors
Cone dystrophy often runs in families and is caused by changes in genes that guide cone cells in the retina. Different inheritance patterns—autosomal dominant, autosomal recessive, or X‑linked—can shape the age at onset and how fast vision changes. Many different genes can be involved, each affecting how cones sense light or stay healthy. Carrying a genetic change doesn’t guarantee the condition will appear.
Autosomal dominant: A single altered gene from an affected parent can cause cone dystrophy, with a 50% chance of passing it to each child. Severity and age at onset can differ widely within the same family.
Autosomal recessive: The condition appears when someone inherits two nonworking copies, one from each carrier parent. This pattern is more likely when parents share extended family roots. It often starts earlier in life, and early symptoms of cone dystrophy may include light sensitivity and color problems.
X-linked inheritance: Changes on the X chromosome tend to affect males more, while females may be carriers with mild or patchy findings. Family trees may show affected males related through female relatives.
CNGA3/CNGB3 variants: Changes in these cone ion-channel genes are a common cause of cone dysfunction in many populations. In some families they are linked to progressive vision problems rather than only static cone loss.
GUCA1A changes: Alterations in this calcium-sensing gene can trigger progressive cone dystrophy. They are usually inherited in an autosomal dominant pattern.
GUCY2D variants: This gene affects the signaling pathway inside photoreceptors that helps them recover after light exposure. Dominant variants can cause cone dystrophy or cone‑rod dystrophy with central vision loss.
PRPH2 variants: This gene helps build the outer segments of photoreceptors that capture light. The same change can lead to different patterns across relatives, from macular issues to broader cone dysfunction.
KCNV2 variants: Recessive changes in this voltage-channel gene cause a form of cone dystrophy that often begins in childhood. Family members are typically healthy carriers.
Opsin gene changes: Variants in OPN1LW or OPN1MW on the X chromosome alter the light‑sensitive pigments in red and green cones. This can lead to X‑linked cone dysfunctions, sometimes with color and clarity problems in school‑age boys.
De novo variants: A new genetic change can appear for the first time in a child, without a family history. Parents may have normal vision, yet the change can still be passed to the next generation depending on the gene involved.
Family history: Having relatives with similar cone problems raises the chance that a shared genetic change is present. A detailed family tree can hint at which inheritance pattern is most likely.
Variable expression: The same genetic change can affect people differently, even within one family. Some relatives barely notice color trouble while others develop clear signs consistent with cone dystrophy.
Lifestyle risk factors
Lifestyle habits do not cause cone dystrophy, but they can influence how symptoms show up day to day and may affect long-term retinal stress. The goal is to reduce phototoxic and oxidative stress, support retinal nutrition, and protect remaining vision. Below are lifestyle risk factors for cone dystrophy and practical ways to adjust them. Evidence is still growing, so discuss changes with your eye specialist.
Intense sunlight or high-brightness environments without UV/blue‑filter protection can increase phototoxic stress on cone cells and aggravate photophobia. Consistent use of UV400 sunglasses, brimmed hats, and appropriate indoor tints may reduce cumulative light stress.
Tobacco smoke increases oxidative stress and depletes macular pigments, which can worsen central vision and color discrimination in cone dystrophy. Quitting smoking may help preserve remaining cone function.
Diets low in lutein, zeaxanthin, and omega‑3s may reduce macular pigment and retinal resilience, aggravating glare and contrast issues. Eating leafy greens and fish (e.g., salmon, sardines) may support contrast sensitivity and visual comfort.
Heavy drinking increases oxidative stress and can deplete B vitamins, potentially intensifying color vision deficits and visual fatigue. Limiting alcohol may help stabilize visual function and overall eye health.
Risk prevention
There’s no known way to stop the genetic changes that cause cone dystrophy, but you can lower light-related stress on the retina and catch issues early. Prevention is about lowering risk, not eliminating it completely. Regular care may help avoid preventable damage and protect everyday vision. Planning for family risks and using eye-safe habits can make a meaningful difference.
A genetics visit can clarify how cone dystrophy runs in your family and the chance of passing it on. Options like carrier testing and in‑vitro fertilization with embryo testing may be discussed.
Wear UV400 sunglasses and a brimmed hat outdoors to reduce retinal light stress. Indoors, consider tinted lenses or filters to cut glare and photophobia.
See an eye doctor routinely for tracking, including retinal imaging as advised. Early checks can spot treatable problems, such as swelling, before they affect vision.
Review your medications and supplements with your doctor to avoid drugs that can stress the retina. Do not start high‑dose eye supplements without medical advice.
Transmission
Cone dystrophy is not contagious. You cannot catch it from someone else, and it doesn’t spread through touch, the air, or bodily fluids.
Most cases are inherited and run in families, and how Cone dystrophy is inherited can follow autosomal dominant, autosomal recessive, or X‑linked patterns. With these, the chance for each pregnancy is typically 50% when a parent has an autosomal dominant form, 25% when both parents are recessive carriers, and sex‑specific in X‑linked families (sons of a carrier mother have about a 50% chance of being affected, while daughters are more often carriers and may have milder changes). Genetic transmission of Cone dystrophy can also happen through a new (de novo) gene change, so it may appear even when there’s no known family history.
When to test your genes
Consider genetic testing if you have progressive vision loss, light sensitivity, color vision changes, or a family history of cone dystrophy. Testing helps confirm the diagnosis, estimate risk for relatives, guide monitoring (eye exams, low-vision care), and match you to clinical trials or gene-specific therapies. Ask earlier if symptoms start in childhood or multiple relatives are affected.
Diagnosis
You might notice small changes in daily routines, like colors looking washed out or bright light feeling uncomfortable. For many, these early symptoms of cone dystrophy show up during school or work tasks that rely on color or reading fine print. Early and accurate diagnosis can help you plan ahead with confidence. Doctors confirm the diagnosis of cone dystrophy by combining eye exams, imaging, electrical tests of the retina, and sometimes genetic testing.
Doctors usually begin by asking about light sensitivity, color changes, and central blur or waviness. Describing when symptoms started and how they affect reading, driving, or screens helps guide testing.
A detailed family and health history can help identify inheritance patterns. Sharing who else has color or vision problems can point toward cone dystrophy or related conditions.
Standard charts check clarity of central vision, which often declines first in cone dystrophy. Color vision tests look for red‑green or blue‑yellow confusion and reduced color intensity.
The eye doctor examines the retina and macula to look for typical patterns, such as a ring-like change around the center. In early stages, the back of the eye can look nearly normal, so further tests are important.
Stages of Cone dystrophy
Cone dystrophy does not have defined progression stages. The course differs widely—some people notice slow changes over many years, while others stay fairly steady for long periods—so there isn’t a single, shared pattern to stage. Different tests may be suggested to help confirm the diagnosis and track changes over time. Early symptoms of cone dystrophy often include difficulty with fine detail, glare or light sensitivity, and color problems, so regular eye checks and follow-up imaging or ERG testing can show how your vision is doing.
Outlook and prognosis
Looking ahead can feel daunting, but many people with cone dystrophy find ways to adapt—tinted lenses for bright light, larger text on screens, and planning travel before dusk. The outlook is not the same for everyone, but most people notice increasing trouble with central vision, color discrimination, and glare sensitivity over years rather than weeks. Some people experience a slow, stepwise decline, while others notice long plateaus where vision is stable. Mortality is not increased by cone dystrophy itself; the condition primarily affects vision and daily tasks that rely on sharp central sight.
Prognosis refers to how a condition tends to change or stabilize over time. In cone dystrophy, central vision often worsens first, which can make reading, recognizing faces, and driving in daylight difficult; peripheral vision and night vision may remain better for longer, especially if the rods are less affected. Early symptoms of cone dystrophy can include light sensitivity and color changes, and these may progress to legal blindness in the central field, though complete blindness is uncommon. When doctors talk about “remission,” they mean symptoms have eased or disappeared for a while, but true remissions are unusual here; stability periods can occur, especially in adulthood.
With ongoing care, many people maintain independence using low-vision tools, orientation training, and workplace or classroom adjustments. Talk with your doctor about what your personal outlook might look like, including whether genetic testing could clarify the subtype and rate of change. Not everyone with the same gene change will have the same outlook, and lifestyle factors like eye protection from bright light may help with comfort and function. Knowing what to expect can ease some of the worry, and it makes planning for driving alternatives, reading aids, and regular follow-up more straightforward.
Long-term effects
Many living with cone dystrophy notice that bright light and fine-print tasks gradually become harder over the years. Vision changes typically center on clarity, color, and how the eyes handle glare. Long-term effects vary widely, and the pace of change can differ from one person to another. Some people plateau for years, while others experience a slow, steady shift in central vision.
Sharp central vision often declines, making reading and recognizing faces harder. Peripheral vision usually stays better preserved, especially early on. In advanced stages, vision can meet legal blindness thresholds.
Bright light can feel harsh and cause significant glare. Early symptoms of cone dystrophy often include discomfort outdoors or in stores with strong lighting. Many describe washed-out or shimmering images in bright settings.
Colors may look faded or less distinct, and telling similar shades apart can be difficult. Over time, this can progress to more severe color vision loss.
A dim or missing area can develop in the center of the visual field. This central scotoma tends to enlarge slowly, affecting detail work and face recognition.
How is it to live with Cone dystrophy?
Living with cone dystrophy often means learning to navigate a world where bright light feels harsh, colors lose their punch, and fine details blur, especially in the center of vision. Many find daily tasks like reading small print, recognizing faces across a room, or driving in daylight challenging, and they build workarounds—tinted lenses, larger text, magnifiers, high-contrast settings, and good task lighting—to stay independent. Friends, family, and coworkers may notice a need for more time, closer distances, or different lighting, and simple adjustments—announcing your presence, offering high-contrast materials, choosing seats away from glare—can make a big difference. With low-vision services, assistive technology, and thoughtful planning, many continue school, work, and hobbies, adapting as vision changes while protecting eye comfort and safety.
Treatment and drugs
Cone dystrophy treatment focuses on protecting remaining vision, easing symptoms, and supporting daily life, since there’s currently no cure to restore cone cells. Although living with cone dystrophy can feel overwhelming, many people manage their symptoms and live fulfilling lives. Tinted or polarized lenses, hats, and screen filters can reduce light sensitivity and glare; high-contrast settings, large-print apps, magnifiers, and electronic readers often make reading and work easier. Low-vision rehabilitation, orientation and mobility training, and occupational therapy help people adapt at home, school, and work, while treating related issues like dry eye or refractive errors with lubricating drops or updated glasses/contacts can improve comfort. Research is ongoing into gene-based therapies and retinal implants; ask your doctor about clinical trials and whether vitamin A or other supplements are advisable for your specific type, as needs vary.
Non-drug treatment
Living with cone dystrophy often means managing light sensitivity, central blur, and color changes rather than taking a specific medicine. Non-drug treatments often lay the foundation for keeping daily tasks doable and protecting remaining vision. Addressing early symptoms of cone dystrophy—like glare discomfort or trouble reading small print—can help you stay active at school, work, and home. Plans are tailored to your vision level, age, and goals.
A low-vision specialist teaches techniques and tools to make the most of remaining sight. Training is personalized to your goals, such as reading mail, using a phone, or cooking safely.
Special tints reduce glare and light sensitivity, a hallmark in cone dystrophy. Different colors and densities are tried to find the one that improves comfort and contrast.
Handheld, stand, or electronic magnifiers enlarge print for reading and labels. A specialist helps match the magnifier strength and working distance to your needs.
You learn to use an area just off the center of vision to see faces or print more clearly. Practice can make this feel more natural during daily tasks.
Your genes may have an impact on how drugs work for you
Medications sometimes used for cone dystrophy symptoms—like treatments for associated inflammation, edema, or light sensitivity—can work differently depending on genes that affect drug breakdown and transport. Pharmacogenetic testing may guide dosing or drug choice to maximize benefit and minimize side effects.
Pharmacological treatments
Cone dystrophy doesn’t yet have a drug that restores cone cells, but medicines can help treat complications—especially macular swelling—and ease day-to-day symptoms like glare. Drugs that target symptoms directly are called symptomatic treatments. These options won’t change early symptoms of cone dystrophy, yet they can improve vision quality and comfort for some people. Treatment is individualized based on what your eye exam shows over time.
Acetazolamide (oral) and dorzolamide or brinzolamide (eye drops) can reduce cystoid macular edema to sharpen central vision. Doctors monitor for side effects like tingling, taste changes, or, with pills, fatigue and stomach upset.
Ketorolac or nepafenac drops may help calm retinal inflammation linked to macular swelling. These are often used with other therapies and need steady, daily use to see benefit.
Prednisolone acetate or loteprednol can be added short term if swelling persists. Your eye doctor will watch eye pressure and adjust or taper to reduce steroid-related risks.
Ranibizumab, aflibercept, or bevacizumab may be used if rare abnormal vessels (choroidal neovascularization) develop and threaten vision. Injections are given in the clinic at set intervals and adjusted based on retinal scans.
Genetic influences
In many people, cone dystrophy is linked to inherited changes in genes that guide how the eye’s cone cells work. Family history is one of the strongest clues to a genetic influence. Patterns vary: in some families it passes from one generation to the next; in others, both parents carry a silent change and a child is affected; some forms are tied to the X chromosome, and a few appear with no prior family history. These genetic differences can shape the age when early symptoms of cone dystrophy start, how quickly vision changes, and whether light sensitivity or color problems stand out most. Genetic testing may find the specific change, though not all causes are known and some results are uncertain; results can also help estimate risks for children and siblings. A consultation with a genetic counselor can help interpret findings and plan follow-up eye care and family planning.
Is Cone dystrophy genetic?
Genetics plays a major role in cone dystrophy; many cases are inherited, with autosomal dominant, autosomal recessive, or X-linked patterns. Specific gene variants can affect age of onset and severity. Genetic testing helps confirm diagnosis, guide counseling, and inform family risks.
Pharmacogenetics—how genetics influence drug effects
Drug treatment options for cone dystrophy are limited, and most care focuses on managing symptoms and complications such as light sensitivity, color vision changes, and occasional retinal swelling. A confirmed genetic result can shape these choices: it identifies the exact gene involved, helps doctors decide which therapies are sensible, and flags things to avoid. For example, when cone dystrophy is caused by ABCA4 changes, many specialists advise against high‑dose vitamin A supplements because they may increase harmful byproducts in the retina. Pharmacogenetic testing doesn’t give a “yes or no” on a single best medicine, but it can guide eligibility for gene‑targeted clinical trials and future therapies, which often require knowing the specific gene. Not every difference in response is genetic, but disease stage, imaging findings, and other health conditions also influence whether treatments like carbonic anhydrase inhibitors for macular swelling are likely to help. Genetic findings won’t change early symptoms of cone dystrophy, yet they can personalize monitoring, inform supplement safety, and prepare you for emerging gene‑based options.
Interactions with other conditions
Day-to-day, people with cone dystrophy who also have diabetes, cataracts, or glaucoma may notice bigger swings in clarity, contrast, and glare sensitivity, especially in bright light. Shared genetic variants may explain why certain conditions cluster together, so relatives might have related macular disorders like Stargardt disease or a cone‑rod dystrophy rather than cone dystrophy itself. In older adults, age‑related macular degeneration can add central blind spots on top of the color and light‑sensitivity problems of cone dystrophy, making reading and face recognition more difficult. If migraine with visual aura is present, temporary shimmering or blind patches can be confused with early symptoms of cone dystrophy, so tracking when and how changes appear can help your eye specialist sort this out. Certain medicines that affect the retina (for example, some antimalarials used for autoimmune disease) can further stress already vulnerable cone cells, so coordinated care is important. When cone dystrophy occurs as part of a broader inherited syndrome, hearing, heart, or nerve issues may also be present, and a team approach can streamline testing, monitoring, and treatment.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described fading color vision and trouble seeing in bright daylight, often starting in childhood or the teen years. A child squinting on the playground, a teenager choosing the back row in a sunny classroom—many families noticed these patterns long before there was a name. Over time, these everyday clues formed the early picture of what we now call cone dystrophy, a condition that primarily affects the light-sensing cone cells in the retina.
First described in the medical literature as a problem of central and color vision, cone dystrophy was initially recognized through careful observation: people struggled with glare, colors washed out, and reading became harder even when side vision seemed fine. Early reports focused on symptoms more than causes. As better eye exams and imaging appeared in the 20th century, doctors could see telltale changes in the macula—the area responsible for sharp, detailed sight—confirming what people had long reported.
With each decade, testing grew more precise. The development of electroretinography allowed clinicians to measure cone function directly, showing reduced cone responses even when the back of the eye looked nearly normal. This helped separate cone dystrophy from other retinal conditions that can look similar at first glance and clarified that, for many, night vision from rod cells was relatively preserved in early stages.
Advances in genetics reshaped the story. Researchers identified changes in several genes that can impair cone health, explaining why cone dystrophy runs in some families and why its course can vary—from slowly progressive loss over many years to more rapid change. DNA research now explains patterns families noticed generations ago, linking shared symptoms to inherited variants and revealing that different gene changes can lead to similar clinical pictures.
In recent decades, awareness has grown that cone dystrophy is not a single path; some people develop symptoms in childhood, while others notice them in adulthood. Imaging tools like optical coherence tomography have mapped subtle thinning of cone-rich layers, and newer color-vision tests have refined how progression is tracked. Despite evolving definitions, the core experience has remained consistent: increasing sensitivity to light, fading colors, and a gradual decline in central detail.
Looking back helps explain current care. Today’s approach—combining history, specialized vision testing, retinal imaging, and genetic analysis—builds on centuries of observations. That long arc has moved cone dystrophy from a set of puzzling symptoms to a well-characterized retinal condition with clearer paths for diagnosis, counseling, and future research.